Losartan

For an informed discussion with your doctor or pharmacist. This information collection is not a clinically validated interaction checker. Missing data do not establish safety. Do not change or stop prescribed medicines on the basis of this information. The findings apply to the specific conditions studied; laboratory and animal studies cannot be directly extrapolated to humans.

Active substance: Losartan

Examples of brand names: Lorzaar [DE]

ATC code: C09CA01

Main use (for orientation): Hypertension

Documented research summary

Existing human cocktail study with CBD 640 mg plus THC 20 mg: losartan AUC +77%; THC 20 mg alone without an inhibition signal. Not CBD-only evidence. A new BV2 glial-cell paper shows a combination effect on NO, not clinical neuroprotection.

Uncertainties and limitations

PMC10671332 abstract states losartan 5 µM, while results/Fig. 2 state 10 µM; contradiction explicitly retained.

A change in parent-substance AUC is not a measured change in overall effect.

Separately recorded findings

3 separately recorded findings. Each statement applies to its documented study context.

CBD + Δ9-THC (oral extract) – clinically studied

Finding ID: B0022

Type of result: Positive finding / indication

Observation: AUC +77%.

Mechanism: CYP2C9 probe

Study type: Randomised crossover pharmacokinetic study

Context studied: n=18; losartan 25 mg within a shared CYP probe cocktail 30 minutes after CBD-rich plant extract (640 mg CBD plus 20 mg THC) in a brownie versus placebo. Double-blind randomised crossover; at least one-week washout; standardised low-fat breakfast one hour before the brownie; sampling 0–24 hours.

Clinical interpretation: Pharmacokinetic signal; clinical consequences undetermined

Limitations and uncertainties: Not a CBD-only study.

Original sources for this finding: Evaluation of Cytochrome P450-Mediated Cannabinoid-Drug Interactions in Healthy Adult Participants [CL09]

Δ9-THC (oral extract without CBD) – clinically studied

Finding ID: B0027

Type of result: No / minor effect under the conditions studied

Observation: No inhibition signal.

Mechanism: CYP probe

Study type: Randomised crossover pharmacokinetic study

Context studied: n=18; losartan 25 mg within a shared CYP probe cocktail 30 minutes after THC plant extract (20 mg THC, no CBD) in a brownie versus placebo. Double-blind randomised crossover; at least one-week washout; standardised low-fat breakfast one hour before the brownie; sampling 0–24 hours.

Clinical interpretation: Null finding

Limitations and uncertainties: Single administration; no general assurance of safety.

Original sources for this finding: Evaluation of Cytochrome P450-Mediated Cannabinoid-Drug Interactions in Healthy Adult Participants [CL09]

CBD – laboratory and animal studies

Finding ID: B0397

Type of result: Preclinical combination effect

Observation: The combination reduced NO release more than individual treatments (approximately 80% versus 22%/26% in the experiment described).

Mechanism: Combined modulation of LPS-induced NO release

Study type: BV2 microglial cells in vitro

Context studied: CBD 5 µM; losartan 5 µM in the abstract, 10 µM in results/Fig. 2. Three independent experiments, n=12 measurements; 24 hours.

Clinical interpretation: Interpret within the stated study context; no independent dosage or treatment recommendation.

Limitations and uncertainties: Contradictory losartan concentration in the original. Not a human blood-pressure, neuroprotection or pharmacokinetic study.

Original sources for this finding: An Emerging Strategy for Neuroinflammation Treatment: Combined Cannabidiol and Angiotensin Receptor Blockers Treatments Effectively Inhibit Glial Nitric Oxide Release. [RMED38003444]

References and access status

[RLABEL_D0217] LOSARTAN POTASSIUM (LOSARTAN POTASSIUM) TABLET, FILM COATED [REMEDYREPACK INC.]

Original source / bibliographic reference

Authors: Regulatory product information; respective marketing authorisation holder

Year: 2026

Source type: Product information / SmPC / US Prescribing Information

Source access – 23 October 2026: Source destination was accessible when checked.

Bibliographic attribution or source identity cross-checked.

[CL09] Evaluation of Cytochrome P450-Mediated Cannabinoid-Drug Interactions in Healthy Adult Participants

Original source / bibliographic reference

Authors: Bansal S; Zamarripa CA; Spindle TR; Weerts EM; Thummel KE; Vandrey RG; Paine MF; Unadkat JD

Year: 2023

Source type: Randomised placebo-controlled crossover probe study

DOI: 10.1002/cpt.2973

PMID: 37313955

Source access – 23 October 2026: Direct retrieval could not be fully verified; availability remains unresolved.

Bibliographic attribution or source identity cross-checked.

DOI – publisher access (access restrictions may apply)

PubMed Central – full-text access according to the literature database – Archive attribution confirmed by Europe PMC metadata. Direct retrieval was not fully verified here; access may require a browser check.

Europe PMC – full-text access according to the literature database – Listed as freely available HTML full text in the official Europe PMC metadata. Direct retrieval was not fully verified here.

[RMED38003444] An Emerging Strategy for Neuroinflammation Treatment: Combined Cannabidiol and Angiotensin Receptor Blockers Treatments Effectively Inhibit Glial Nitric Oxide Release.

Original source / bibliographic reference

Authors: Fleisher-Berkovich S, Battaglia V, Baratta F, Brusa P, Ventura Y, Sharon N, Dahan A, Collino M, Ben-Shabat S.

Year: 2023

Source type: Original publication; see finding for study type

DOI: 10.3390/ijms242216254

PMID: 38003444

Source access – 23 October 2026: Automated direct retrieval was restricted; this does not establish that the link is broken.

Bibliographic attribution or source identity cross-checked.

PubMed – bibliographic reference / abstract

PubMed Central – full-text access according to the literature database – Archive attribution confirmed by Europe PMC metadata. Direct retrieval was not fully verified here; access may require a browser check.

Europe PMC – full-text access according to the literature database – Listed as freely available HTML full text in the official Europe PMC metadata. Direct retrieval was not fully verified here.

Research as of 23 October 2026. Not all original full texts could be reviewed in full. Source accessibility and the strength of scientific evidence must be assessed separately. An accessible link does not establish medical approval; a bibliographic record with an abstract does not replace the original full text.

Drug search and explanation of the evidence · Guide: cannabinoids and medicines · Author and responsibility